Hims CEO Defies FTC Regulatory Crackdown
The public clash between Hims & Hers CEO Andrew Dudum and the Federal Trade Commission (FTC) marks a critical inflection point for the direct-to-consumer (DTC) digital healthcare industry. The regulatory pressure targets the core of the telehealth provider's business model, particularly its aggressive expansion into compounded GLP-1 weight-loss medications and artificial intelligence-driven diagnostics.